Showing 2681-2690 of 7413 results for "".
- New Option for Molluscum Expected Soonhttps://practicaldermatology.com/news/New-Option-Molluscum-Expected-Soon/2471226/Perhaps the most important measure a dermatologist can take after diagnosing a patient with molluscum is to reassure them that it is not a big deal, Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, said at Winter Clinical Hawaii 2025 in Waikoloa Village, Hawaii.
- 'Dr. Pimple Popper' Offers Social Media Advicehttps://practicaldermatology.com/news/Dr-Pimple-Popper-Offers-Social-Media-Advice/2471209/Social media transformed Sandra Lee, MD, FAAD, FAACS, into “Dr. Pimple Popper.” While not every dermatologist aspires to have their own television show, many would like to maximize the impact of their social media presence, and Dr. Lee shared pearls from her own experience at the Winter Clinical
- Dupixent Moves Closer to FDA Approval for Bullous Pemphigoidhttps://practicaldermatology.com/news/dupixent-moves-closer-to-fda-approval-for-bullous-pemphigoid/2471173/Dupixent® (dupilumab) significantly improved sustained disease remission in adults with bullous pemphigoid (BP) compared to placebo, according to an announcement from the manufacturers, Regeneron Pharmaceuticals and Sanofi. Acc
- 2% Medicare Payment Increase Could Be Imminenthttps://practicaldermatology.com/news/2-Medicare-Payment-Increase-Could-Be-Imminent/2471172/A 2% payment increase for physicians from Medicare appears close after American Academy of Dermatology (AAD) president Seemal Desai, MD, FAAD, attended a congressional session on February 11. “This bill has so much momentum that we are finally on the cusp,” Dr. Desai said during an AAD upd
- Nemolizumab Approved by European Commission for Moderate-to-severe Prurigo Nodularishttps://practicaldermatology.com/news/nemolizumab-approved-european-commission-for-moderate-to-severe-prurigo-nodularis/2471164/Nemolizumab has been approved by the European Commission for the treatment of moderate-to-severe prurigo nodularis, according to an announcement from Galderma. The approval of the monoclonal antibody (marketed as Nemluvio) fol
- New Dupilumab Data for CSU to Be Presented at AAAAI Meetinghttps://practicaldermatology.com/news/New-Dupilumab-Data-CSU-Be-Presented-AAAAI-Meeting/2471105/New phase 3 data on dupilumab for chronic spontaneous urticaria (CSU) will be among 24 abstracts presented by Sanofi at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Diego, California, from February 28 to March 3. The dupilumab CSU data from the LIBER
- Study: Newer Biologics Do Not Increase MACE/VTE Risk in PsO/PsAhttps://practicaldermatology.com/news/Study-Newer-Biologics-Do-Not-Increase-MACE-VTE-Risk-PsO-PsA/2471065/A new emulated target trial analysis found no significant risk differences in major adverse cardiovascular events (MACE) or venous thromboembolic events (VTE) in patients with psoriasis or psoriatic arthritis treated with IL-17, IL-12/23, or IL-23 inhibitors vs those treated with TNF inhibitors.<
- Study Shows Oral Minoxidil Improves Patient Outcomes for Hair Losshttps://practicaldermatology.com/news/study-shows-oral-minoxidil-improves-patient-outcomes-for-hair-loss/2471041/New research in the Journal of Drugs in Dermatology shows oral minoxidil outperforming topical formulations in terms of patient adherence, satisfaction, and ease of use, without significantly increasing systemic side effects. Researchers on the study studied 50 patients using eith
- Cosmetic Laser Market to Reach $14.79 Billion by 2033: Reporthttps://practicaldermatology.com/news/cosmetic-laser-market-to-reach-1479-billion-by-2033-report/2471023/The global cosmetic lasers market is projected to grow to $14.79 billion by 2033, at a compound annual growth rate (CAGR) of 14%, according to a new report from Straits Research. The analysis said the growth reflects increasing consumer interest in minimally invasive cosmetic procedures f
- IgE Identified as Key Mediator in Psoriasis and Atherosclerosis Comorbidityhttps://practicaldermatology.com/news/ige-identified-as-key-mediator-in-psoriasis-and-atherosclerosis-comorbidity/2471009/A new review points to immunoglobulin E (IgE) as a potential central player in the overlapping mechanisms of psoriasis and atherosclerosis. Researchers writing in Biomedicine and Pharmacotherapy proposed IgE-mediated mast cell (MC) activation as a significant contributor to the progressio